Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이오영 | - |
dc.date.accessioned | 2018-02-28T02:20:17Z | - |
dc.date.available | 2018-02-28T02:20:17Z | - |
dc.date.issued | 2016-04 | - |
dc.identifier.citation | JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, v. 22, NO 2, Page. 254-263 | en_US |
dc.identifier.issn | 2093-0879 | - |
dc.identifier.issn | 2093-0887 | - |
dc.identifier.uri | http://www.jnmjournal.org/journal/view.html?doi=10.5056/jnm15178 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/40982 | - |
dc.description.abstract | Background/Aims The effect of proton pump inhibitors (PPI) in Asian functional dyspepsia (FD) patients has not been well established as in Western countries. DA-9701, a novel prokinetic agent, stimulates gastric emptying and modulates visceral hypersensitivity in vivo and in human studies. This study was conducted to compare the efficacy of DA-9701 with a conventional PPI in mono or combination therapy in patients with FD. Methods In this double-blind, randomized, non-inferiority trial, 389 patients diagnosed with FD using Rome III criteria were allocated among 3 groups: 30-mg DA-9701 t.i:d (means 3 times a day), 40-mg pantoprazole, and 30-mg DA-9701 t.i.d + 40-mg pantoprazole. The primary efficacy end-point was a global assessment of the patient binary response or response on a 5-Likert scale after 4 weeks. Results The global symptomatic improvement was 60.5% in the DA-9701 group, 65.6% in the pantoprazole group, and 63.5% in the DA-9701 + pantoprazole group using a 5-Likert scale at week 4 with no significant difference among 3 groups (P = 0.685). Symptom improvement measured by binary outcome was significantly achieved in each of the 3 groups, but not different among groups. Patients in all treatment groups reported significant improvement in the response rate and symptoms according to FD subtypes and dyspepsia-related quality of life (P ˂ 0.001), but there were no significant differences among the 3 groups. Conclusions DA-9701 improves global and individual symptoms and increases dyspepsia-specific quality of life in patients with FD. The efficacy of DA-9701 monotherapy is comparable with pantoprazole and there is no additive effect with combination of DA-9701 and pantoprazole in patients with FD. | en_US |
dc.language.iso | en | en_US |
dc.publisher | KOREAN SOC NEUROGASTROENTEROLOGY & MOTILITY | en_US |
dc.subject | DA-9701 (Motilitone) | en_US |
dc.subject | Dyspepsia | en_US |
dc.subject | Proton pump inhibitor | en_US |
dc.title | Efficacy of DA-9701 (Motilitone) in Functional Dyspepsia Compared to Pantoprazole: A Multicenter, Randomized, Double-blind, Non-inferiority Study | en_US |
dc.type | Article | en_US |
dc.relation.no | 2 | - |
dc.relation.volume | 22 | - |
dc.identifier.doi | 10.5056/jnm15178 | - |
dc.relation.page | 254-263 | - |
dc.relation.journal | JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY | - |
dc.contributor.googleauthor | Jung, Hye-Kyung | - |
dc.contributor.googleauthor | Lee, Kwang Jae | - |
dc.contributor.googleauthor | Choi, Myung-Gyu | - |
dc.contributor.googleauthor | Park, Hyojin | - |
dc.contributor.googleauthor | Lee, Joon Seong | - |
dc.contributor.googleauthor | Rhee, Poong-Lyul | - |
dc.contributor.googleauthor | Kim, Nayoung | - |
dc.contributor.googleauthor | Park, Kyung Sik | - |
dc.contributor.googleauthor | Choi, Suck Chei | - |
dc.contributor.googleauthor | Lee, Oh Young | - |
dc.relation.code | 2016012070 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | leeoy | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.